Idexx Laboratories price target lowered to $520 from $600 at Piper Sandler

Piper Sandler lowered the firm’s price target on Idexx Laboratories to $520 from $600 following animal health survey, while keeping an Overweight rating on the shares. Piper is taking down its Q4 numbers slightly to reflect foreign exchange impacts, and its 2024 estimates to reflect potential recessionary impacts.